CD79B and diffuse large B-cell lymphoma: Mutations of CD79b are observed in 23% of activated b-cell (ABC) subtype R/R DLBCL [37], yet, the initial studies of Pola-BR showed clinical efficacy regardless of cell of origin [20, 38].